Illumina weakness ‘overdone,’ says Wolfe Research
Wolfe Research reiterated an Outperform rating and $150 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about ...
Roche SBX announcement creates more uncertainty for Illumina, says RBC
RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its ...
precisionmedicineonline7h
Intellia Therapeutics' In Vivo CRISPR Drug Could Offer One-Time Fix for ATTR Amyloidosis
A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...
FierceBiotech8h
Illumina maps out entry into spatial transcriptomics
Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...
GlobalData on MSN10h
Illumina teases transcriptome profiling tech ahead of 2026 launch
Set for release in 2026, the ‘first-of-its-kind’ technology aims to give researchers the ability to analyse more cells in a ...
eLife23h
Multi-Omics Single-Cell Analysis Reveals Key Regulators of HIV-1 Persistence and Aberrant Host Immune Responses in Early Infection
This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...
Nature23h
AI tool diagnoses diabetes, HIV and COVID from a blood sample
One-shot’ approach that uses machine learning to screen immune cells could help to detect conditions with overlapping ...